BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

275 related articles for article (PubMed ID: 24027671)

  • 1. State-of-the-Art Research on "Lymphomas: Role of Molecular Imaging for Staging, Prognostic Evaluation, and Treatment Response".
    Kostakoglu L; Cheson BD
    Front Oncol; 2013 Sep; 3():212. PubMed ID: 24027671
    [TBL] [Abstract][Full Text] [Related]  

  • 2. 18F-fluorodeoxyglucose positron emission tomography in the staging and prognosis of T cell lymphoma.
    Casulo C; Schöder H; Feeney J; Lim R; Maragulia J; Zelenetz AD; Horwitz S
    Leuk Lymphoma; 2013 Oct; 54(10):2163-7. PubMed ID: 23369041
    [TBL] [Abstract][Full Text] [Related]  

  • 3. 2-[18F]fluoro-2-deoxyglucose positron-emission tomography in staging, response evaluation, and treatment planning of lymphomas.
    Specht L
    Semin Radiat Oncol; 2007 Jul; 17(3):190-7. PubMed ID: 17591566
    [TBL] [Abstract][Full Text] [Related]  

  • 4. More advantages in detecting bone and soft tissue metastases from prostate cancer using
    Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
    Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Controversies on the prognostic value of interim FDG-PET in advanced-stage Hodgkin lymphoma.
    Adams HJ; Kwee TC
    Eur J Haematol; 2016 Dec; 97(6):491-498. PubMed ID: 27528557
    [TBL] [Abstract][Full Text] [Related]  

  • 6. 18F-Fluorodeoxyglucose Positron Emission Tomography/Magnetic Resonance in Lymphoma: Comparison With 18F-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography and With the Addition of Magnetic Resonance Diffusion-Weighted Imaging.
    Giraudo C; Raderer M; Karanikas G; Weber M; Kiesewetter B; Dolak W; Simonitsch-Klupp I; Mayerhoefer ME
    Invest Radiol; 2016 Mar; 51(3):163-9. PubMed ID: 26784400
    [TBL] [Abstract][Full Text] [Related]  

  • 7. FDG-PET/CT in the management of lymphomas: current status and future directions.
    El-Galaly TC; Villa D; Gormsen LC; Baech J; Lo A; Cheah CY
    J Intern Med; 2018 Oct; 284(4):358-376. PubMed ID: 29989234
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Discrepancies and priorities in staging and restaging malignant lymphoma by SPET, SPET/CT, PET/CT and PET/MRI.
    Chavdarova LI; Tzonevska AD; Piperkova EN
    Hell J Nucl Med; 2013; 16(3):223-9. PubMed ID: 24137584
    [TBL] [Abstract][Full Text] [Related]  

  • 9. FDG-PET/CT in lymphoma.
    Juweid ME
    Methods Mol Biol; 2011; 727():1-19. PubMed ID: 21331925
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [F-18 fluorodeoxyglucose positron emission tomography in malignant lymphoma].
    Mikosch P
    Wien Med Wochenschr; 2002; 152(11-12):269-75. PubMed ID: 12138654
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Interim 18F-FDG PET in Hodgkin lymphoma: would PET-adapted clinical trials lead to a paradigm shift?
    Kostakoglu L; Gallamini A
    J Nucl Med; 2013 Jul; 54(7):1082-93. PubMed ID: 23818548
    [TBL] [Abstract][Full Text] [Related]  

  • 12. PET/CT for Lymphoma Post-therapy Response Assessment in Other Lymphomas, Response Assessment for Autologous Stem Cell Transplant, and Lymphoma Follow-up.
    Karls S; Shah H; Jacene H
    Semin Nucl Med; 2018 Jan; 48(1):37-49. PubMed ID: 29195616
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Overview of the clinical effectiveness of positron emission tomography imaging in selected cancers.
    Facey K; Bradbury I; Laking G; Payne E
    Health Technol Assess; 2007 Oct; 11(44):iii-iv, xi-267. PubMed ID: 17999839
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The evolving role of response-adapted PET imaging in Hodgkin lymphoma.
    Coyle M; Kostakoglu L; Evens AM
    Ther Adv Hematol; 2016 Apr; 7(2):108-25. PubMed ID: 27054026
    [TBL] [Abstract][Full Text] [Related]  

  • 15. PET-CT in Staging, Response Evaluation, and Surveillance of Lymphoma.
    Thanarajasingam G; Bennani-Baiti N; Thompson CA
    Curr Treat Options Oncol; 2016 May; 17(5):24. PubMed ID: 27032646
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The role of FDG-PET in Hodgkin lymphoma.
    Subocz E; Hałka J; Dziuk M
    Contemp Oncol (Pozn); 2017; 21(2):104-114. PubMed ID: 28947879
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The role of 18F-FDG PET and 18F-FDG PET/CT in the evaluation of pediatric Hodgkin's lymphoma and non-Hodgkin's lymphoma.
    Qiu L; Chen Y; Wu J
    Hell J Nucl Med; 2013; 16(3):230-6. PubMed ID: 24137577
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Staging and response assessment in lymphomas: the new Lugano classification.
    Cheson BD
    Chin Clin Oncol; 2015 Mar; 4(1):5. PubMed ID: 25841712
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Importance of PET/CT in lymphoma diagnostics].
    Afshar-Oromieh A; Kratochwil C; Haberkorn U; Giesel FL
    Radiologe; 2012 Apr; 52(4):338-46. PubMed ID: 22526115
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Imaging for diagnosis, staging and response assessment of Hodgkin lymphoma and non-Hodgkin lymphoma.
    McCarten KM; Nadel HR; Shulkin BL; Cho SY
    Pediatr Radiol; 2019 Oct; 49(11):1545-1564. PubMed ID: 31620854
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.